VENTURA COUNTY
HEALTH CARE PLAN

Prior Authorization DRUG Guidelines

Cuvposa (glycopyrrolate, oral)

Effective Date: 10/22/13
Date Developed: 9/3/13 by Albert Reeves MD
Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20

Cuvposa is a muscarinic anticholinergic agent that does not cross the blood-brain barrier.

Pre-Authorization: to reduce chronic severe drooling in patients with neurologic conditions associated with problem drooling (e.g. cerebral palsy)

Off-Label: adjunct with acetylcholinesterase inhibitors (eg, neostigmine, edrophonium, pyridostigmine) to antagonize cholinergic effects

Dosing: Initiate at 0.02 mg/kg orally three times daily and titrate in increments of 0.02 mg/kg every 5-7 days based on therapeutic response and adverse reactions. The maximum recommended dosage is 0.1 mg/kg three times daily not to exceed 1.5-3 mg per dose based upon weight. Administer at least one hour before or two hours after meals.

PRECAUTIONS: High fat food reduces the oral bioavailability. Constipation. Heat stroke in susceptible individuals. Drowsiness. Blurred vision. Dry mucus membranes.

DRUG INTERACTIONS: anticholinergic drugs (e.g. ipratropium), drugs with anticholinergic side effects, cholinergic drugs (e.g. pyridostigmine [Mestinon])

REFERENCES

D'Urzo A, Ferguson GT, van Noord JA, et al, "Efficacy and Safety of Once-Daily NVA237 in Patients With Moderate-to-Severe COPD: The GLOW1 Trial," *Respir Res*, 2011, 12:156.

Kerwin E, Hébert J, Gallagher N, et al, "Efficacy and Safety of NVA237 versus

Placebo and Tiotropium in Patients With COPD: The GLOW2 Study," *Eur Respir J*, 2012, 40(5):1106-14.

Sechaud R, Renard D, Zhang-Auberson L, et al, "Pharmacokinetics of Multiple Inhaled NVA237 Doses in Patients With Chronic Obstructive Pulmonary Disease (COPD)," *Int J Clin Pharmacol Ther*, 2012, 50(2):118-28.

Revision History:

Date Approved by P&T Committee: 10/22/13
Date Reviewed/No Updates: 1/28/14 by C. Sanders MD
Date Approved by P&T Committee: 1/28/14
Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/Updated: 2/17/15 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19
Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/20

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
2/18/20	No	Howard Taekman, MD; Robert Sterling, MD	Annual review